A better understanding of the cytoskeletal mechanisms that regulate PLT formation and determine PLT size offers the promise of improved therapies for clinical disorders of PLT production and an important source of PLTs for infusion. In the first half of this review advances in the understanding of terminal PLT production are summarized individually under their respective title headings. In the second half of this review common underlying connections deriving from these studies are examined collectively to establish a mechanistic model of PLT formation and size determination.
Platelet production from bone marrow megakaryocytes
The proPLT model of PLT formation recognizes that differentiated MKs extend long, branching processes, designated proPLTs, which are comprised of PLT-sized swellings in tandem arrays that are connected by thin cytoplasmic bridges. 1 From as early as 1969, physiological evidence of proPLT production has been supported by multiple images of proPLTs extending into the sinusoidal blood vessels of the bone marrow [2] [3] [4] . Extracellular matrix (ECM) proteins are a major constituent of the bone marrow vascular niche, and have been shown to promote proPLT formation in vitro 5, 6 . Nevertheless, how MKs establish the polarity needed to direct proPLT . These barbell structures have also been identified in the whole blood of rats 10 and guinea pigs 11 .
In 2007 Junt et al. used live imaging with multiphoton intravital microscopy to visualize
PLT production in vivo 12 . While bone marrow MKs were shown extending proPLTs into sinusoidal blood vessels 13, 14 , the majority of shed fragments were larger than PLTs, and confirmed that proPLTs were being released into the circulation. Originally proposed by Behnke and Forer in 1998 15 , this study renewed support for the prediction that PLT morphogenesis continues in the vasculature, possibly assisted by intravascular shear forces.
Terminal platelet production occurs in the bloodstream
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From While the relative contributions of various organs to platelet production is still controversial, examination of whole blood in rats has revealed that proPLT production significantly increases following acute blood loss 10 . In these studies blood proPLT concentrations in right ventricles were significantly higher than in left ventricles of healthy animals. Likewise, reports of higher PLT counts in post-pulmonary vessels suggests that the lung may be a milieu for terminal PLT formation 16 . Indeed, the lung is the first capillary bed encountered by any cell leaving the bone marrow and in humans it has been reported that 10-times as many intact megakaryocytes are found in the pulmonary arterial blood than in blood collected from the aorta 17 . Nevertheless, mice treated to perturb normal thrombopoiesis (platelet antiserum, 5-fluorouracil, and radioactive strontium) still contain significantly fewer megakaryocytes in the liver and lung than in the bone marrow or spleen (which were greatly increased over controls) 18 . While this implies that the bone marrow and spleen are the major thrombopoietic organs in mice, proPLTs released from these sites may become trapped in the micro-capillaries of the lung where intravascular shear forces can drive PLT production. Indeed, MKs infused into mice retro-orbitally or by tail vein mostly localize to the pulmonary vasculature, where they result in clinically relevant increases in PLT numbers over a period of 12-24 hrs
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. Likewise, CMFDA-labeled proPLTs are not detected in recipient mouse blood post-infusion despite observations that CMFDA-labeled PLT counts increase significantly over the same period of time
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. Identification and subsequent elaboration of microenvironments supporting thrombocytopoiesis will yield approaches to accelerate PLT production in-vivo and establish bioreactors to replicate this process in culture.
The prePLT
In 2011 a new intermediate stage in the maturation process called the prePLT was discovered (Figure 1 ) 20 . PrePLTs were defined as anucleate PLT progenitors, 3-10 μ m across, and may be related to 'young (reticulated) PLTs' associated with increased RNA content, and 'large PLTs' of inherited/acquired macrothrombocytopenias. Originally isolated from mouse megakaryocyte cell cultures, we have recently identified circular-prePLTs in human whole blood 21 . These dynamic intermediate structures reversibly convert into barbell-shaped proPLTs that divide to form two PLTs. Indeed, PLT distribution curves are known to be markedly asymmetrical (with newly-formed PLTs exhibiting larger dimensions than PLTs of a normal population) 22 , and the frequency distribution of PLT volume histograms are significantly changed in cases of severe 23 .
PrePLTs have yet to be isolated from MK cultures and whole blood apart from PLTs, and their functionality remains to be characterized.
The duplicating PLT
The discovery of a prePLT intermediate coincided with observations by Schwertz et al. that anucleate human PLTs, maintained in suspension at 37°C, became larger and gave rise to new cell bodies packed with respiring mitochondria and alpha-granules 24 . Since increasing PLT numbers were not generally observed during PLT unit storage it has been proposed that PLTs might respond to decreases in local concentration by initiating duplication. Barbell-proPLT conversion in both human and mouse cultures were followed by the formation of a cleavage furrow along the long shaft between the two PLT-sized tips that may denote the point of division 20, 24 . Newly formed PLTs were structurally indistinguishable from blood PLTs, adhered and spread on ECM, and displayed normal signal-dependent expression of surface P-selectin and Annexin V 24 , suggesting that subpopulations of duplicating human PLTs may be analogous to prePLTs. Although a biomarker to distinguish between late-stage intermediates of PLT production and terminally differentiated PLTs is currently lacking, ongoing efforts to discover these will be paramount in resolving the mechanism of PLT duplication. Supporting this endeavor is the observation that human PLT progeny formation is accompanied by increases in protein synthesis and mitochondrial DNA replication, and translational inhibition with puromycin reduced the development of new cell bodies in these cultures 24 . The observation that PLTs are capable of continued protein translation during culture 25, 26 has raised the question of whether the entire PLT proteome needs to be replicated to support PLT duplication or if translation of just a subset of this proteome is sufficient.
Acquired thrombocytopenias
Acquired thrombocytopenia is a major clinical problem encountered across a number of conditions, including immune (idiopathic) thrombocytopenic purpura (ITP), myelodysplastic syndromes, aplastic anemia, human immunodeficiency virus infection, major cardiac surgery, chemotherapy and radiation-induced thrombocytopenia ( Figure 1 ). The latter represents the most common cause of low PLT counts in clinical hematology and oncology, and it has been estimated that 300,000 persons yearly worldwide undergo courses of chemotherapy adequate to
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From produce clinically significant thrombocytopenia 27 . Understanding the molecular basis of PLT size is also important because subjects with abnormally high PLT volumes have enhanced platelet reactivity and may be at risk for recurrent ischemic coronary syndromes 28 . 'Large PLTs' often occur concomitantly with periods of low PLT counts in humans 22 and increased PLT size may be due to drug-induced effects on proPLT production and PLT release, or specific enlargement of circulating PLTs due to disruption of the cytoskeletal components regulating their peripheral microtubule coil 21 . Alternatively, circulating prePLTs may represent newly released, young PLTs during rebound from PLT clearance. In addition to being larger, young
PLTs are also more granulated, and more reticulated (express higher concentrations of mRNA, mitochondrial DNA, and dense granules) than the majority of circulating PLTs in normal controls, which should set them apart from duplicating PLTs [29] [30] [31] [32] [33] [34] . While the distinction between duplicating and young PLTs is important to make, the increased concentration of barbell-proPLT and circular-prePLT structures in stored PLT cultures and thrombocytopenic patient blood is not mutually exclusive and may represent a dynamic intermediate stage common to both.
Genetic regulators of PLT size
The fact that baseline peripheral blood cell parameters are influenced by genetics is firmly established, as heritability estimates derived from studies of PLT counts in twins has shown. traits and diseases [37] [38] [39] . Genome-wide scans of QTL for PLT count and MPV in F 2 intercrosses between NZW/LacJ, SM/J, and C57BLKS/J inbred mice revealed 3 significant QTL for baseline PLT count, and 2 significant QTL for MPV 36 . Of these, 3 specific genes stand out: Tub2a (α2 tubulin), Tuba6 (α6 tubulin), and Nfe2 (nuclear factor, erythroid derived 2) encoding the 45 kDa subunit of the heterodimeric transcription factor NF-E2 40, 41 .
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Likewise, whole-blood measurements in 683 normal human subjects also reveals that there is a nonlinear, inverse relation between PLT count and MPV in humans 42 , and implies that PLT number and size are fundamentally governed by a conservation of mass. This observation was most recently confirmed during a high-powered meta-analysis of genome-wide association studies in 66,876 individuals of European ancestry 43 . In this study Gieger et al. identified 68
genomic loci reliably associated with PLT count and volume mapping to established and putative novel regulators of megakaryopoesis and PLT formation 43 . Interestingly, many of the genes identified also correlated with known regulators of macrothrombocytopenia.
Inherited human macrothrombocytopenias
Among those genes most prominently expressed in Gieger's study were GPIbα, GPIX, and von
Willebrand Factor (VWF), associated with Bernard-Soulier syndrome; GPIIb, associated with
Glanzmann's thrombasthenia; NF-E2; and β 1-tubulin. One of the most distinguishing features of the resting PLT is its marginal microtubule coil 44 . α β tubulin dimers polymerize into microtubules under physiological conditions, and are a key component of proPLT formation and PLT release 45, 46 . Likewise, the transcription factor p45 NF-E2, whose downstream targets include both the MK-and PLT-specific β 1-tubulin, and Rab27b, is required for PLT formation (see 'The microtubule cytoskeleton') 40, 41, [47] [48] [49] . These data suggest that macrothrombocyopenias are in essence defects in terminal PLT production, and may therefore offer direct insight as to the biophysical properties governing barbell-proPLT conversion and PLT release. Below are the best characterized instances of inherited human macrothrombocytopenias, categorized by the cellular component affected.
Glycoprotein expression
Glanzmann's thrombasthenia is caused by mutations in the ITGA2B or ITGB3 genes that encode for the integrin α IIb β 3 and results in a severe PLT bleeding disorder due to a limited ability to bind fibrinogen 50 . Although PLT counts are typically normal in this disease, the recent discovery of autosomal dominant macrothrombocytopenias associated with PLT dysfunction has suggested that β 3 integrin and its β -terminal domain are required for regulating normal proPLT formation and terminal PLT size 50, 51 . While proPLT-extension in the p.D647_E686del mutation has yet to be examined, in vitro differentiated MKs with the β 3 -D723H mutation exhibit larger proPLT tips 37 . This is characteristic of many human macrothrombocytopenias, and suggests that the inability to further constrict proPLT ends prior to abcission may account for terminal PLT size.
T-box containing transcription factor 1. DiGeorge or velocardiofacial syndrome is believed to be caused by a haploid insufficiency of a single gene, TBX1 (encoding a T-box containing transcription factor) 52 , and can show autosomal recessive inheritance, although it is mostly acquired. Phenotypic features include conotruncal cardiac abnormalities, learning disabilities, velopharyngeal insufficiency, immunodeficiency, facial dysmorphism and thymic hypoplasia 53 .
While approximately 20% of patients express mild thrombocytopenia and increased PLT size, it should be noted that the GP1BB gene sits adjacent to TBX1, and its deletion can give rise to
Bernard-Soulier syndrome in a compound heterozygote when accompanied by a pathological mutation in the GATA binding site of the remaining GPIbβ allele 54, 55 . Indeed, hemizygosity of GPIbβ in the 22q11.2 deletion syndrome is associated with macrothrombocytopenia in humans 55 , as is targeted GPIBB disruption in mice 56 , suggesting that haploinsufficiency of GPIBB in the right genetic background may be more related to PLT size and number than the absence of TBX1. Further work is therefore necessary to establish the significance of TBX1 in terminal PLT production.
Glycoprotein Ib. First described more than 60 years ago, Bernard-Soulier syndrome is an autosomal recessive macrothrombocytopenia linked to genetic lesions of the GPIb-IX-V complex that result in defective ristocetin-induced PLT agglutination, a lack of VWF-dependent PLT adhesion to subendothelium, and reduced thrombin-induced PLT aggregation 53, 57 . Normal numbers of MKs are generally found in the bone marrow of these patients which implies that the macrothrombocytopenia is related to an error in the terminal stages of PLT production. MKs exhibit disordered and vacuolated invaginated membrane systems 57 . Platelet counts in BernardSoulier syndrome mostly range from 40,000/µL to near normal, and are also associated with abundant cytoplasmic vacuoles and an abnormal concentration of membrane complexes in discrete zones 53 . GPIbα is most frequently affected in Bernard-Soulier syndrome and GPIbα knock-out mice recapitulate all the hallmarks of Bernard-Soulier syndrome 57, 58 . In variant Bernard-Soulier syndrome, while non-functional GPIbα is partially expressed on the PLT 53 . Conversely, knocking out GPV in mice has no effect on MK ultrastructure and development of the invaginated membrane system, PLT production, size, adhesion, or GPIb-IX expression, and is consistent with the fact that no mutation in the GPV gene has yet been described in Bernard-Soulier syndrome 59 .
The microtubule cytoskeleton
PLT shape and integrity is maintained by a well-defined and highly specialized cytoskeleton comprised of an intricate system of molecular struts and girders that also regulate PLT size. The 
The actin cytoskeleton
Little is known about the role of actin in proPLT production. Similar to tubulin, actin is in a dynamic monomer-polymer equilibrium. Actin filaments crosslink at various points to generate stiff cytoplasmic networks that intersect the microtubule cytoskeleton. Repeated actin-dependent bending and branching that bifurcates the proPLT shaft is common, and serves to increase the number of free proPLT ends from which platelets are thought to release 61 . Knocking out both ADF and n-cofilin severely limits proPLT extension, prevents formation of PLT-sized buds at proPLT tips, and virtually abolishes PLT release 74 .
Actin interacting protein 1 (Aip1), a cofilin-interacting protein has been shown to enhance cofilin's capacity to sever actin filaments, and may accelerate depolymerization by capping their barbed ends [75] [76] [77] [78] . Mutation in the gene encoding the mammalian homolog of Aip1, WD40-repeat protein 1 (Wdr1), causes profound megakaryocytosis and macrothrombocytopenia in mice 79 .
Taken together, these data suggest that actin filament turnover plays a critical role in PLT production, and the terminal stages of PLT release.
Myosin IIA. Myosin IIA, the non-muscle myosin heavy chain product of the MYH9 gene, has also been implicated in restraining proPLT formation in developing MKs 80 . Indeed, Arp2/3 complex contribution to actin filament nucleation in PLTs requires free barbed ends generated by severing and uncapping pre-existing actin filaments 92 .
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CD34
+ cells isolated from the blood and marrow of these patients exhibited normal MK differentiation and proPLT formation in culture, and released PLTs of normal size 93 .
Interestingly, mouse models of Wiskott-Aldrich syndrome also produce PLTs of normal size and exhibit only mild thrombocytopenia. 94 MKs 
The spectrin-based membrane skeleton
The PLT membrane skeleton consists of elongated spectrin strands that interconnect through actin filament binding 95 . This network is comprised of both erythroid and non-erythroid spectrins that laminate the cytoplasmic surface of both the open-canalicular and plasma membrane systems 96 . The invaginated membrane system of MKs is thought to supply membrane during proPLT formation and is also largely supported by a spectrin-based membrane skeleton 96 .
Expression of the spectrin tetramer-disrupting construct spα2N1 inhibits invaginated membrane system maturation and proPLT production in MKs, and rapidly destabilizes proPLT extensions in proPLT-producing MKs, causing blebbing and swelling 96 . In permeabilized barbell-proPLTs, addition of spα2N1 converts these cells to spheres, demonstrating that membrane skeletal continuity maintains the elongated, pre-fission shape thought to regulate terminal PLT production 96 . Mouse models of spectrin deficiencies have also been tied to abnormal PLT function, including stroke and thrombus formation 97, 98 . In humans, mutations in ANKRD26 have recently been associated with thrombocytopenia without macrocytosis 99 . Ankyrin protein is responsible for attachment of integral membrane proteins to the spectrin-actin based membrane skeleton and confirms that spectrin assembly is a critical factor in PLT formation.
For
Cytoskeletal model for PLT production
The production of PLTs by MKs requires an intricate series of cytoskeletal-driven remodeling events that result in the release of thousands of PLTs from a single progenitor. The formation of proPLTs and the final release step of PLTs have many things in common. Both involve elongation, dramatic membrane reorganization, and forces derived from the cytoskeleton.
Because of pronounced similarities in morphogenesis, elucidation of the structural mechanics of proPLT formation is likely to provide insights into how terminal PLT size is established. Central to MK differentiation is the development of the invaginated membrane system, an expansive and interconnected membrane network of cisternae and tubules that are continuous with the plasma membrane, and function as a membrane reservoir during proPLT production. Erythroid and nonerythroid spectrins that laminate the cytoplasmic surface of the invaginated membrane system provide the skeletal structure necessary to support its formation. 96 To assemble and release PLTs, MKs evaginate their membranes to form large pseudopodia that elongate, thin, bend, and branch into multiple proPLT projections with PLT-size swellings at their ends.
Early in the maturation process, before erosion of the cell body begins, the MK cytoplasm is replete with long individual arrays of microtubules that cluster around the nucleus and radiate toward the cell margins. As proPLT production initiates, microtubules consolidate into cortical bundles situated just beneath the membrane surface of the first pseudopodia extended. The developing proPLT shafts lengthen and taper as the microtubules that fill them undergo a thinning phase (to ~20 microtubules), looping around the proPLT tip and reentering the shaft to form tear-drop shaped buds at their ends 61 . Repeated actin-dependent bending and branching bifurcates the proPLT shaft, and serves to increase the number of free proPLT ends. 61 Branching initiates when a proPLT shaft is bent into a sharp kink, which eventually folds back upon itself, forming a loop in the microtubule bundle. As this loop elongates it forms a new proPLT shaft branching from the side of the original proPLT. Thickenings along the proPLT shaft, while superficially resembling PLT bodies, do not contain microtubule rings characteristic of the tips, but are instead comprised of parallel microtubule bundles that diverge for short distances and then rejoin 1 . While these swellings appear at regular intervals along proPLT extensions, they are not larger in MK models of human macrothrombocytopenia and their
purpose has yet to be resolved.
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As proPLTs mature and are ultimately released, peripheral microtubule coils at the proPLT tips assume a uniform thickness of ~7 microtubules and diameter of ~2 µm that is consistent with terminal PLT size. Released proPLTs retain the same dimensions as the branched extensions of proPLT-producing MKs and it is easiest to consider their morphology apart from the larger MK body. In released proPLTs the microtubule bundle is best regarded as a nodespring-loop (akin to an elastic band) that stretches as microtubules are slid apart, and compresses as they are brought together (Figure 1 ). Since released proPLTs form barbells in culture with narrow corridors and tear-drop-shaped ends instead of circles of increasing or decreasing diameters, these deformations must be constrained by external compressive pressures.
The actin-based cytoskeleton and spectrin-based membrane skeleton are attractive candidates for these compressive forces. Disorders in actin/myosin organization (as is the case for Filaminopathy A, ADF/n-cofilin knock outs, and MYH9 related disorders) result in increased proPLT end-sizes and PLT diameters. Likewise, megakaryocytic defects in the amino-terminal domain of highly expressed trans-membrane receptors (as is the case for Glanzmann's thrombasthenia, DiGeorge/Velocardiofacial syndrome, and Bernard-Soulier syndrome) disrupt connection of the plasma membrane to the actin cytoskeleton and exhibit disordered and vacuolated invaginated membrane systems in addition to producing larger proPLT end sizes and PLT diameters. Indeed, treatment of proPLTs with the actin-destabilizing drugs latrunculin and cytochalasin D increase the peripheral microtubule coil diameter of the proPLT tips while addition of the actin-stabilizing drug jasplankinolide to proPLTs constrict it 21 . The spectrin-based membrane skeleton, by comparison, provides structural integrity to preserve the long, tubular shape of proPLT projections without which they assume a swollen appearance and released barbell-proPLTs become sphericized 96 .
Mathematical modeling of the interplay between the expansion force generated by microtubule coil sliding and/or polymerization at the proPLT tip, and the compressive force deriving from the actin-myosin-spectrin cortex have allowed us to address how terminal PLT size is established 21 . This model predicts that final PLT size is determined by the balance between microtubule bundling and bending forces, such that when characteristic protein forces and microtubule rigidity are factored in, the predicted PLT radius is in the micron range.
Biological examples of human/murine macrothrombocytopenia have confirmed these predictions and shown that PLT size increases slowly as the microtubule number in the peripheral bundle ProPLTs are released by bone marrow MKs into sinusoidal blood vessels and fragment into individual PLTs while circulating in whole blood 12 . Quantification of PLT production from released proPLTs in culture reveals that PLTs are generated at an increasing rate in time as large proPLTs undergo repeated abscissions along their mid-bodies 20 . Barbell-shaped proPLTs represent the penultimate step in this continuum from which two-individual PLTs are generated.
During maturation barbell-proPLTs revert to circular-prePLTs by untwisting their peripheral microtubule coil 20 . Whole blood-derived prePLTs are cytoplasmically indistinguishable from young (reticulated) PLTs and contain comparable numbers of peripheral microtubules. The increased concentration of large PLTs in the circulation of both humans and mice in instances of increased PLT clearance such as antibody-mediated thrombocytopenia implies that prePLTs are a dynamic intermediate stage in PLT production. Given the low relative concentration of barbellproPLTs (0.05%) versus circular-prePLTs (3.63%) in venous blood, it is likely that once circular-prePLTs convert into barbell-proPLTs, abscission is rapid 21 . Alternatively, prePLTs may become trapped in the micro-capillaries of the bone marrow, lung and/or spleen where intravascular shear forces can drive PLT production. Indeed, reports of higher PLT counts in post-pulmonary vessels suggests that the lung may be a milieu for terminal PLT formation 16 .
Mathematical modeling of circular-prePLT-to-barbell-proPLT conversion based on the balance of microtubule bundling, elastic bending, and actin-spectrin-myosin cortex forces predict that force constraints resulting from cortical microtubule band diameter and thickness determine barbell-proPLT formation and limit PLT size 21 . Membrane skeletal continuity, by comparison, maintains the elongated, pre-fissile shape of the barbell-proPLT and may regulate terminal PLT Taken together these data demonstrate that in proPLT-producing MKs membrane receptors interact through microtubules, actin, and spectrin to provide both the static and dynamic framework necessary to regulate terminal PLT size. These features of living architecture are the same principles that govern tensegrity architecture, and will require a paradigm shift in the way we frame questions of PLT production 85 . It should not be surprising that the net balance of competing internal/external forces maintain cell shape during thrombocytopoiesis. Motor proteins such as dynein, kinesin and myosin are known to regulate cellular architecture during proPLT formation. Nevertheless, these observations emphasize the need for biophysical approaches to model proPLT-production where the mechanical properties of extracellular matrices such as rigidity and patterning, and environmental influences such as shear are as important as ECM protein-and growth-factor-dependent signaling through specific membrane receptors [100] [101] [102] .
Conclusions
The transition from MK to PLT is a complex process. Although the basic mechanisms of proPLT Further examination of genetic defects resulting in PLT disorders, and the continued molecular and biochemical study of MKs as they transition into PLTs is needed before these questions can ultimately be answered. For
